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Abstract: The Escherichia coli Cytotoxic Necrotizing Factors, CNF1, CNF2, CNF3 and 
CNFY from Yersinia pseudotuberculosis belong to a family of deamidating toxins. CNFs 
deamidate glutamine 63/61 in the switch II region of Rho GTPases that is essential for 
GTP hydrolysing activity. Deamidation leads to constitutive activation of Rho GTPases. 
However, cellular mechanisms like proteasomal degradation of the activated Rho proteins 
restrict the action of the GTPases. This review describes the differences between the toxin 
family members concerning expression, cellular entry and substrate specificity. 
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1. Introduction 
 
Small GTP binding proteins of the Rho family have been identified as common targets of bacterial 
toxins.  The  GTPases  are  involved  in  the  regulation  of  several  cellular  processes  including  
re-organization of the cytoskeleton, endo- and exocytosis, cell proliferation and apoptosis (for review 
see  [1]).  They  act  as  ―on-off‖  switches,  cycling  between  an  inactive,  GDP-bound  state  and  an 
activated, GTP-bound state, which is recognized by effector molecules. Activation occurs by guanine 
nucleotide exchange factors (GEFs) that catalyze the release of the bound nucleotide and therefore the 
exchange of GDP for GTP. Like all small GTPases, Rho proteins return to the GDP-bound state by 
intrinsic  or  GTPase  activating  protein  (GAP)-stimulated  hydrolysis  of  GTP.  Additional  factors 
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regulating Rho GTPase activity and function are GDIs (Guanine nucleotide Dissociation Inhibitors), 
which sequester GDP-bound Rho proteins in the cytosol or mediate the transport of the activated 
GTPases to other cellular locations. 
The first toxins known to modify Rho GTPases led to complete inactivation of the proteins. C3-like 
toxins from Clostridium botulinum, Clostridium limosum and Staphylococcus aureus ADP-ribosylate 
Asn41  of  RhoA.  This  modification  enhances  the  affinity  for  GDI  and  thereby  inhibits  nucleotide 
exchange, which besides other effects leads to inhibition of RhoA-dependent signalling pathways. 
The  large  clostridial  cytotoxins  Clostridium  difficile  toxins  A  and  B,  which  are  implicated  in 
antibiotic-associated  diarrhea  and  pseudomembranous  colitis,  glucosylate  RhoA  at  Thr37.  This 
modification blocks the interaction of the GTPase with effector proteins. Also Rac and Cdc42 are 
inactivated. Other members of this toxin family like Clostridium sordellii lethal toxin possess different 
substrate specificity and modify Rac but not RhoA. In addition, Ras subfamily proteins (e.g., Ras, Ral 
and Rap) are modified (for review see [2]).  
The  first  toxin  described  to  dominantly  activate  Rho  GTPases  was  the  Cytotoxic  Necrotizing  
Factor 1 (CNF1), which is produced by pathogenic Escherichia coli strains. It obtained its name from 
its necrotizing effect on rabbit skin when it was isolated and tested [3]. CNF1 is the best analysed 
member of the growing toxin family with identical (CNFs) or similar (DNT, Dermonecrotic Toxin) 
activities described below.  
Uropathogenic Escherichia coli (UPEC) are one of the most prevalent strains in infections of the 
urinary tract [4,5]. It is generally accepted, that most of the UPEC strains live in the intestine and enter 
the urinary tract via the urethra. While acute urinary tract infections (UTI) can be treated with common 
antibiotics, the chronic recurring UTIs are a bigger threat. They bear a growing risk of septicaemia due 
to the invasion of bacteria into the bloodstream.  
CNF1 is a major virulence factor of UPEC strains [6]. It is associated with several other virulence 
factors  like  aerobactin,  P  fimbriae  and  hemolysin.  The  gene  for  hemolysin  shows  the  strongest 
correlation to cnf1 in UPEC strains. It was reported, that 98% of cnf1+ strains were also positive for 
hly [7]. Rippere-Lampe et al. could show that cnf1+ strains exhibit a significantly higher survivability 
in  the  UTI  mouse  model  [8].  The  infection  with  cnf1+  UPEC  is  accompanied  by  an  increased 
inflammation rate, as it was also reported by Fournout et al. [9]. However, recent studies show, that 
CNF is not only associated with uropathogens. It also is associated with skin and soft tissue infections 
[10]. Moreover, CNF1 is produced in some extraintestinal E. coli (ExPEC). It has been reported for E. 
coli K1, that CNF1 increases the invasion of brain microvascular endothelial cells (BMEC) [11]. This 
invasion requires cytoskeletal rearrangements due to the activation of RhoA. E. coli K1 is one major 
pathogen participating in neonatal meningitis [5]. In a recent study, it was shown that of 60 patients 
who died of septicaemia, CNF1 producing E. coli were isolated from the blood of 22% of the patients 
[12].  CNF1  was  found  in  bacteria  isolated  from  meningitis  affected  children.  CNF2  has  been 
demonstrated in E. coli isolated from calves and lambs with diarrhoea [13], whereas CNF3 has been 
identified in Necrotoxigenic Escherichia coli (NTEC) from healthy sheep and goats [14]. In contrast to 
CNF1 and CNF3, which are chromosomally encoded, CNF2 is located on a transmissible plasmid [15]. 
PCR studies showed that the gene for CNF1 is more common than that for CNF2 [16]. 
Many studies describe CNF1 as an important virulence factor in bacterial infections: E. coli strains, 
which are CNF1-deficient, have less potential to colonize the urinary tract [17]. Moreover, CNF1 is Toxins 2010, 2                                       
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responsible  for  tissue  damage  and  disturbs  the  epithelial  barrier  function  as  determined  in  tissue 
culture  systems  [18,19]  and  affects  the  function  of  immune  cells  by  blocking  phagocytosis  [20]. 
Induction  of  phagocytic  behaviour  of  non-phagocytic  cells,  and  inhibition  of  phagocytosis  in 
monocytes  was observed  following  CNF1 intoxication  of cultured  cells  [17]. There are  hints  that 
CNF1 may be involved in cancer development: CNF1 induces the expression of cyclooxigenase-2 
(COX-2),  activates  nuclear  factor-kappa  B  (NF-κB),  increases  cell  motility  and  inhibits  
apoptosis [21–23]. 
 
2. Mode of Action 
 
All toxins which activate Rho GTPases by covalent modification modify the same amino acid in 
Rho GTPases (glutamine 63 in RhoA or its homolog in other Rho proteins is crucial for the GTPase 
activity).  CNFs  catalyse  the  deamidation  of  this  glutamine  [24,25].  Therefore,  GTP  hydrolysis  is 
blocked, which results in continuous effector activation (Figure 1). Meanwhile four CNF isoforms are 
known: CNF1, CNF2 (85% sequence identity with CNF1) and CNF3 (70% sequence identity with 
CNF1)  from  Escherichia  coli  and  CNFY  (61%  sequence  identity  with  CNF1)  from  Yersinia 
pseudotuberculosis.  The  Dermonecrotic  Toxin  (DNT)  from  Bordetella  spp.,  which  has  sequence 
homology to the CNFs exclusively in the catalytic domain, transamidates glutamine 63 of RhoA [26]. 
DNT is able to catalyse deamidation of RhoA, but favours transamidation [27,28]. Both modifications 
lead to inhibition of the intrinsic and GAP-stimulated GTPase activity. However, attachment of a 
primary amine (e.g., spermidine, putrescine or lysine) to RhoA by transamidation induces a different 
phenotype  on  mammalian  cells  as  compared  to  the  phenotype  induced  by  deamidation.  This  is 
probably, because the attached amine inhibits some protein-protein interactions [29]. Under certain in 
vitro conditions, CNF1 is able to catalyze transamidation, but primarily, it acts as a deamidase [30]. 
Unexpectedly, deamidated RhoA shifts to higher molecular weight in SDS-PAGE, although the mass 
increase due to deamidation is only 1 Da. The same shift can be observed with recombinant proteins 
(wildtype  RhoA  and  RhoA-Q63E).  Obviously  the  amino  acid  composition  rather  than  further 
modifications in the living cell are the reason for the apparent mass increase. In contrast, transamidated 
RhoA with a much higher mass increase migrates at lower molecular weight [24]. Modification of 
Rac1 or Cdc42 cannot be monitored by SDS PAGE.   
Due  to  the  constitutive  activation  of  Rho-GTPases,  CNF1-intoxication  induces  characteristic 
morphological changes in mammalian cells [31]. The most striking differences occur by changes of the 
actin cytoskeleton. Constitutive activation of RhoA leads to the formation of stress fibers, which are 
contractile bundles of parallel actin filaments and myosin. Rac activation leads to the formation of 
lamellipodia,  which  require  a  net-like  organisation  of  filamentous  actin.  The  toxins  also  induce 
filopodia, finger like structures, due to the activation of Cdc42-dependent pathways. Besides extreme 
flattening of the cell body, culture cells acquire a multinucleated phenotype. This is considered to 
simply arise from inhibited cytokinesis with ongoing nuclear division [32]. However, nuclei do not 
divide equally. Division is asymmetric and aneuploidy is induced [33].  
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Figure 1. Activation of Rho GTPases by CNFs. 
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Rho GTPases act as molecular switches in diverse signaling pathways. They are regulated 
in  a  GTPase  cycle  in  which  guanine  nucleotide  exchange  factors  (GEFs)  catalyze  the 
exchange of GDP for GTP. Hydrolysis of GTP is catalyzed by GTPase-activating proteins 
(GAPs).  The  exact  role  of  guanine  nucleotide  dissociation  inhibitors  (GDIs),  which 
sequester Rho GTPases in the cytosol, is not entirely clear. CNFs deamidate glutamine 63 
of  RhoA,  generating  glutamic  acid.  This  leads  to  the  block  of  GTP  hydrolysis  and 
constitutive activation of the G-protein. 
 
CNFs deamidate a single glutamine in the switch II region of Rho GTPases. This glutamine is 
conserved  between  different  members  of  the  Ras  superfamily  of  small  GTPases.  However,  CNFs 
exclusively  deamidate  Rho-proteins.  The  substrate  specificity  differs  between  the  CNF  isoforms. 
CNFY is specific for RhoA, B and C and does not modify Rac or Cdc42 [34]. CNF2 is reported to 
preferentially modify RhoA and Rac [35], whereas CNF1 and CNF3 deamidate RhoA, Rac and Cdc42. 
However, CNF3 activates RhoA much stronger than CNF1 [36].  
Although deamidated Rho GTPases do not hydrolyse GTP and therefore constitutive activation is 
expected, some signalling pathways have been found to be only transiently activated. The reason for 
this transiency lies in the fate of the modified GTPases.  
Following deamidation by CNF1, cellular Rac was found to be ubiquitinated and subsequently 
degraded by a proteasome-dependent mechanism [21,37]. Degradation of other Rho GTPases seems to 
be cell type specific. In HUVEC (human umbilical vein endothelial cells), CNF-activated RhoA and 
Cdc42 are degraded as well [38], whereas in HeLa cells Rac1 is ubiquitinated and degraded, while 
other activated GTPases were found to be stable [39]. Since degradation of Rac increases cell motility 
and  leads  to  enhanced  internalization  of  bacteria,  it  was  speculated  that  sequential  Rho  GTPase 
activation and inactivation limits the inflammatory response and promotes survival of bacteria [21]. 
 
3. Structure-Function Relationship 
 
All  CNFs  are  identical  in  length  (1013/1014  aa  CNFY/CNF1,  2,  3)  and  comprise  a  modular 
structure with an N-terminal receptor binding domain. In conjunction with the central translocation 
domain, it mediates cellular entry (see below). Toxins 2010, 2                                       
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The C-terminal part of CNF1 (aa 720 to 1014) harbours the full catalytic activity [40,41]. Cysteine 
866 and histidine 881 have been found to be crucial for the catalytic activity of CNF1 [41]. The crystal 
structure identified the third residue of the catalytic triad, valine 833 [42]. Moreover, it revealed a 
previously unknown protein fold that is considered to be unique to CNFs (Figure 2). Modelling of the 
CNFY catalytic domain on the CNF1 structure resulted in the same folding [43]. In CNF1 and CNFY 
the centre of the catalytic domain is formed by a -sandwich consisting of two mixed -sheets. It is 
surrounded by -helices and nine loop regions that line the entrance to a deep and narrow pocket with 
the catalytic residues sitting at its base [42]. 
 
Figure 2. Structure of the CNF1 catalytic domain (aa 710–1014). 
 
The catalytic domain is given as ribbon representation. The catalytic residues Cys866 and 
His881 (side chains shown in red and green, respectively) are located at the base of a deep 
pocket lined by flexible loops that may be implicated in Rho-binding (Adapted from [42]) 
using Swiss-PDBViewer 3.7. 
 
The  structure  presented  in  Figure  2  suggests  that  substrate  binding  occurs  by  an  induced  fit 
mechanism, which is dependent on the flexibility of the switch II region of Rho GTPases. This may be 
an explanation for the high substrate specificity of the toxins. Buetow and Gosh have defined two of 
the  surrounding  loops  (loop  8  (aa  964–970)  and  loop  9  (aa  996–1003))  as  important  for  RhoA 
recognition by deleting five of the nine loops in CNF1 [44]. Exchange of these loops between CNF 
isoforms  with  different  substrate  specificity  (CNF1  and  CNFY)  allowed  modulation  of  substrate 
acceptance,  which  underlines  the  relevance  of  the  loop  regions  for  substrate  recognition  and/or  
binding [43]. Toxins 2010, 2                                       
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Cellular uptake of CNFs 
 
The cellular uptake of CNFs is presented in Figure 3. CNF1 enters host cells via receptor-mediated 
endocytosis [45]. The domain which mediates the interaction to the cell surface ranges from aa 53 to 
190 and is able to inhibit the holotoxin activity when given to cells in excess [46]. Using this receptor 
binding domain as a bait in the yeast two hybrid system, the ubiquitously expressed 37-kDa laminin 
receptor precursor (37LRP) could be identified as an interaction partner for CNF1 [47]. 37LRP is 
known to be a precursor protein for the 67-kDa laminin receptor.  Binding studies with CNF1 revealed 
that  the  67-kDa  laminin  receptor  clusters  with  invasive  E.  coli  K1.  This  clustering  is  due  to  the 
expression  of  CNF1  in  these  pathogens  and  promotes  their  invasion  into  cells  [48].  However, 
competition studies with CNF1 and CNFY suggest, that CNF1 has a co-receptor in addition to the 
laminin receptor. Inhibition of heparansulfate proteoglycane (HSPG) expression causes retarded cell 
entry of CNF1 and no uptake of CNFY [49]. Thus, HSPGs may represent the receptor for CNFY and 
the co-receptor for CNF1, respectively. This finding is also consistent with the different spectrum of 
cells,  intoxicated  by  CNF1  and  CNFY,  respectively.  Furthermore,  a  recent  study  also  suggests  a  
co-receptor for CNF1 due to a second receptor binding part within the CNF1 sequence including the 
amino acids 683 to 730 [50].  
The  uptake  of  CNF1  and  CNFY  into  vesicles  is  independent  of  clathrin  and  caveolin  [45,49]. 
Internalized  vesicles  are  acidified  by a vacuolar type H
+-ATPase (v-ATPase) to a pH of 5.5–6.0. 
Decreasing the early endosomal pH is one of the essential steps in toxin translocation. This has been 
shown also for many other AB-type toxins. Endosomal acidification can be blocked by bafilomycin 
A1, a compound from Streptomyces griseus, which inhibits the vesicular type proton pumps [51]. The 
prevention of the endosomal acidification leads to a complete inhibition of CNF activity on cultured 
cells [45]. 
The hydropathy profile of CNF1 shows a potential transmembrane domain between the receptor 
binding and the catalytic domain (aa 300–400). The comparison of the CNF1 primary structure with 
the one of diphtheria toxin (DT) implies the existence of two short membrane spanning helices H1 
(350–372) and H2 (387–412) according to the transmembrane helices TH8 and TH9 in DT [52]. It was 
postulated, that the hydrophilic loop, which separates H1 and H2, is essential for translocation of the 
toxin into the host cell cytosol. According to the diphtheria toxin model,  the acidic milieu in the 
endosome leads to a conformational change of the toxin. This forces the exposure of the hydrophobic 
regions within the translocation domain [53]. 
Coincidentally, the acidic residues in the loop region are protonated and promote the insertion of 
helix 1 and helix 2 into the endosomal membrane. According to this model, mutations of acidic amino 
acids in the loop region result in decreased toxin activity. The charge, as well as the order of these 
residues in the loop-region are crucial for CNF1 translocation [52] (Figure 3). 
Rho  GTPases  as  the  targets  of  CNFs  are  located  in  the  cytosol  and  at  the  plasma  membrane. 
Therefore,  the  catalytic  domain  has  to  be  released  from  the  endosomal  membrane.  Following 
endocytosis, the catalytic domain of CNF1 is cleaved off. The cleavage site is located between amino 
acids 536 and 542, a sequence which does not show any sequence similarities to known protease sites 
[54]. Nevertheless, serine protease inhibitors are able to inhibit the CNF1 deamidating activity as well 
as its processing. Unlike other AB-toxins, autocatalytic cleavage was not identified, indicating that an Toxins 2010, 2                                       
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endosomal protease may be involved in CNF1 processing. Experiments with CNF1 mutants, which are 
deficient in the cleavage site, clearly show that the processing and release of the catalytic part from the 
endosomes is essential for the full biologic activity.  It is likely, that this release occurs from late 
endosomes. Destruction of the microtubules, which are essential for the maturation from early to late 
endosomes, results in weaker CNF1 toxicity [45,49]. 
 
Figure 3. Cellular uptake of CNF1. 
 
(1)  Binding  to  the  67  kDa  laminin  receptor  via  the  CNF1  N-terminus.  (2)  Receptor 
mediated endocytosis. (3) Acidification of the early endosome. (4) Conformational change 
of  CNF1  due  to  the  acidic  milieu  and  insertion  of  the  translocation  domain  into  the 
vesicular  membrane  (5)  Cleavage  of  the  toxin  by  a  serine  protease  and  release  of  the 
catalytically active C-terminus, (6) Deamidation of Rho proteins at Gln63/61 by CNF1.  
 
Export of CNF 
 
Most studies prove the presence of cnf in bacteria by PCR. The amount of protein expressed is 
expected to be very low. This may be the reason, why only little is known about the export of CNFs 
from bacteria. No typical signal peptide is found in the sequence of CNF1. Two groups show that 
CNF1  is  released  from  the  bacteria  to  the  surrounding  environment,  tightly  associated  to  outer 
membrane vesicles. These CNF1-bearing vesicles transfer biologically active CNF1 to mammalian 
cells [55,56]. Studying the genetic determinants for secretion of CNF1 in meningitis-causing E. coli, 
Yu and Kim suggest that ferredoxin is required for the secretion of CNF across the bacterial inner 
membrane [57]. However, the exact transport mechanism of CNFs remains to be analyzed. 
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4. Conclusions 
 
Rho  GTPases  are  master  regulators  of  the  cytoskeleton  and  are  essentially  involved  in  cell 
migration, adhesion, polarity, cell division, neuronal plasticity and many other cellular functions. This 
may be the reason, why Rho GTPases are the targets of various bacterial protein toxins. These toxins 
inhibit or stimulate Rho proteins and modulate the pattern and ratio of their active and inactive forms 
in  eukaryotic  target  cells  and/or  alter  the  expression  and  the  cellular  fate  of  Rho  GTPases. 
Interestingly, inhibition of Rho proteins seems to mediate the same beneficial effects for bacterial 
survival as strong activation does. Bacterial protein toxins are meanwhile widely analyzed and are 
used as important cell biological tools to study the functions of Rho GTPases. Much is known about 
the cellular entry of CNF1 as a prototype for the family of Rho deamidating toxins. It binds to a 
cellular protein receptor and is released following endocytosis and cleavage into the cytosol.  The 
molecular action of the CNFs is known and the structure function relationship widely characterized. 
CNFs constitutively activate Rho GTPases by deamidation of a specific glutamine, required for GTP 
hydrolysis. The substrate specificity varies between different CNF isoforms. Direct activation of Rho 
proteins could be of therapeutic relevance and first attempts to use CNF1 for influencing learning and 
memory or pain have been made [58,59] (summarized in this issue of ―Toxins‖ by Fabbri et al.).  
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